VAP® Lipid Panel Helps Predict Heart Attack Risk and Improved Outcomes in African Americans
In an effort to better identify and treat heart disease among African Americans, researchers today presented findings showing that higher levels of HDL3 subclasses measured with the VAP Lipid Panel were associated with less risk for heart attacks in Jackson Heart Study participants.
The oral abstract #17632 HDL Subclasses are Not All Created Equal: Association of HDL Subclasses and Incident Cardiovascular Events in African Americans from the Jackson Heart Study presented by study lead author Parag H. Joshi, M.D., demonstrated that HDL3 subfraction cholesterol was inversely associated with cardiovascular events, and was the main driver behind the inverse association of HDL cholesterol and cardiovascular risk.
Using the VAP® Lipid Panel from Atherotech Diagnostics Lab for lipoprotein subclass measurement, researchers examining Jackson Heart Study data measured levels of high density lipoprotein cholesterol (HDL) to better identify and characterize risk factors for coronary heart disease (CHD) among African Americans. HDL includes more than a dozen subclasses, but HDL3 (small, dense) and HDL2 (large, buoyant) are recognized for their association with CHD risk. The study measured cholesterol from HDL2, HDL3, and total HDL as well as apolipoproteins A1 and B (apoA1 and apoB) among 4,722 participants.
“The Jackson Heart Study represents an important effort to better understand the higher prevalence of cardiovascular disease among African Americans and uncover new approaches to reduce this disparity,” said Joshi, Clinical Cardiology Fellow, Johns Hopkins Hospital. “As with LDL, we know that all HDL particles are not created equal, and this study marks an important step forward in its findings that HDL3 cholesterol levels are inversely associated with cardiovascular risk. The higher the measured HDL3 cholesterol levels, the lower the risk of fatal heart attacks.”
Researchers also found that the HDL3 subfraction was protective from CHD events overall, independent of apoA1 and apoB levels. The HDL3 subclass explained the trend towards an inverse association of HDL cholesterol with overall CHD.
“The relationship between lipid subfractions and heart disease demands comprehensive and accurate lipid analysis of factors that extend beyond the limitations of the basic lipid panel,” said Chief Medical Officer Michael E. Cobble, M.D. “We're pleased that researchers were able to evaluate the comprehensive, direct measurement capabilities of the VAP Lipid Panel, which ultimately contributes to more personalized treatment and better outcomes.”
For information on the VAP Lipid Panel, visit www.Atherotech.com or call 877.901.8510. Atherotech Diagnostics Lab is on Twitter at www.Twitter.com/Atherotech and also on Facebook at www.Facebook.com/Atherotech.
To arrange interviews with any of these presenters, co-authors or other Atherotech medical experts who will be in attendance and can provide outside comment on these and other sessions, please call 720-231-9990 or e-mail email@example.com. All research results are embargoed until the time they are presented during the conference. All times listed are Pacific Standard Time. Please refer to the American Heart Association for embargo policies pertaining to presentations at the Scientific Sessions.
About Atherotech Diagnostics Lab & the VAP Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech's proprietary and comprehensive VAP® Lipid Panel enables clinicians to accurately stratify a patient's cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company's dedication to affordable, comprehensive disease management solutions includes Our Healthy Heart, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.
Armada Medical Marketing for Atherotech Diagnostics Lab
Dan Snyders, 720-231-9990